[Cited FineTest Antibody] Current Research on SARS-CoV-2 Detection with Aptamer

FineTest antibody contributes to the research on SARS-CoV-2 detection with aptamer. The immunoassay is designed to detect N protein.

Publication Details
Article Title: Robust Covalent Aptamer Strategy Enables Sensitive Detection and Enhanced Inhibition of SARS-CoV-2 Proteins
Journal Title: ACS Central Science
DOI: 10.1021/acscentsci.2c01263
IF: 18.2
PMID: 36712483

Abstract: Aptamer-based detection and therapy have made substantial progress with cost control and easy modification. However, the conformation lability of an aptamer typically causes the dissociation of aptamer-target complexes during harsh washes and other environmental stresses, resulting in only moderate detection sensitivity and a decreasing therapeutic effect. Herein, we report a robust covalent aptamer strategy to sensitively detect nucleocapsid protein and potently neutralize spike protein receptor binding domain (RBD), two of the most important proteins of SARS-CoV-2, after testing different cross-link electrophilic groups via integrating the specificity and efficiency. Covalent aptamers can specifically convert aptamer-protein complexes from the dynamic equilibrium state to stable and irreversible covalent complexes even in harsh environments. Covalent aptamer-based ELISA detection of nucleocapsid protein can surpass the gold standard, antibody-based sandwich ELISA. Further, covalent aptamer performs enhanced functional inhibition to RBD protein even in a blood vessel-mimicking flowing circulation system. The robust covalent aptamer-based strategy is expected to inspire more applications in accurate molecular modification, disease biomarker discovery, and other theranostic fields.

Immunoassay

Validated Image

Figure Source:  ACS Cent Sci. 2023 Jan 2;9(1):72-83. doi: 10.1021/acscentsci.2c01263.